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Background: Fractures of the humeral shaft are associated with a profound temporary (and in the elderly
sometimes even permanent) impairment of independence and quality of life. These fractures can be
treated operatively or non-operatively, but the optimal tailored treatment is an unresolved problem. As no
high-quality comparative randomized or observational studies are available, a recent Cochrane review
concluded there is no evidence of sufficient scientific quality available to inform the decision to operate or
not. Since randomized controlled trials for this injury have shown feasibility issues, this study is designed to
provide the best achievable evidence to answer this unresolved problem. The primary aim of this study is to
evaluate functional recovery after operative versus non-operative treatment in adult patients who sustained
a humeral shaft fracture. Secondary aims include the effect of treatment on pain, complications, generic
health-related quality of life, time to resumption of activities of daily living and work, and cost-effectiveness.
The main hypothesis is that operative treatment will result in faster recovery.
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Methods/design: The design of the study will be a multicenter prospective observational study of 400
patients who have sustained a humeral shaft fracture, AO type 12A or 12B. Treatment decision (i.e., operative
or non-operative) will be left to the discretion of the treating surgeon. Critical elements of treatment will be
registered and outcome will be monitored at regular intervals over the subsequent 12 months. The primary
outcome measure is the Disabilities of the Arm, Shoulder, and Hand score. Secondary outcome measures are
the Constant score, pain level at both sides, range of motion of the elbow and shoulder joint at both sides,
radiographic healing, rate of complications and (secondary) interventions, health-related quality of life
(Short-Form 36 and EuroQol-5D), time to resumption of ADL/work, and cost-effectiveness. Data will be
analyzed using univariate and multivariable analyses (including mixed effects regression analysis). The
cost-effectiveness analysis will be performed from a societal perspective.
Discussion: Successful completion of this trial will provide evidence on the effectiveness of operative versus
non-operative treatment of patients with a humeral shaft fracture.
Trial registration: The trial is registered at the Netherlands Trial Register (NTR3617).Background
Humeral shaft fractures are associated with a profound
temporary (in elderly sometimes even permanent) im-
pairment of independence and quality of life. Fractures
of the humeral shaft account for 1-3% of all fractures
[1]. The cumulative incidence shows a peak in the work-
ing population (14.5/100,000 person years) as well as in
the elderly (60/100,000) [1-3].
Humeral shaft fractures can be treated operatively or
non-operatively. Operative treatment is mostly performed
by intramedullary nailing, plate osteosynthesis, or external
fixation. Non-operative immobilization is mostly done
with a functional (Sarmiento) brace [4]. Operative and non-
operative treatment strategies both have their pros and cons.
Operative fracture fixation allows for early mobilization,
which may lead to earlier functional recovery and reduced
pain. However, surgical complications and fixation failure
may occur [5]. Non-operative treatment may be associated
with more pain (as the fracture is not stabilized) and dis-
comfort (due to pain and immobilization) in the first
weeks and may be associated with a higher malunion risk
due to the lack of fracture re-alignment [6,7]. Longer
immobilization may delay functional recovery.
Complications of operative and non-operative treatment
overlap and data are lacking to determine treatment re-
latedness. Non-union occurs in 15-30% after operative
treatment [5] versus 2-23% after non-operative treatment
(for which most patients require secondary surgical treat-
ment) [6,7]. The most feared disabling complication is ra-
dial nerve palsy, occurring in 2-17% of all patients [8-10].
A systematic review (n = 4,517 patients) reported an aver-
age radial nerve palsy of 11.8%. Although 70% recover
spontaneously, the palsy was permanent in 12% of cases
accounting for a substantial impairment and costs [9].
Regaining function is extremely important from a pa-
tient and societal perspective. From the few retrospective
and prospective case series published, each using otheroutcomes, better functional outcome is expected after op-
erative treatment [8,11-17].
The best type of treatment is still debated. Surgeons state
that their experience, patient characteristics and expected
physical demands in daily living guides treatment decision.
In the elderly patients, some surgeons might prefer
immobilization while others may primarily operate as they
fear inferior functional outcome after non-operative treat-
ment. In younger patients, some surgeons directly perform
a surgical intervention while others primarily choose non-
operative immobilization, followed by surgical intervention
if needed. However, our retrospective study showed an ap-
proximately 50% operation rate irrespective of fracture sub-
class with no obvious differences in patient or fracture
characteristics across classes [18]. Since randomized or
high-quality comparative observational studies are lacking,
a recent Cochrane review concluded there is no evidence of
sufficient scientific quality available to inform the decision
to operate or not [19]. High-quality clinical studies are thus
urgently needed to resolve this clinically relevant problem.
RCTs for this injury have shown feasibility issues; one RCT
continued as an observational study due to severe recruit-
ment problems [20]. The HUMMER study is designed to
provide the best achievable evidence to answer this unre-
solved problem using an observational trial design.
The primary objective of this study is to examine the ef-
fect of operative versus non-operative treatment on the
DASH (Disabilities of the Arm, Shoulder, and Hand)
score, reflecting functional outcome and pain of the upper
extremity, in adult patients who sustained a humeral shaft
fracture. Secondary aims are to examine the effect of op-
erative versus non-operative treatment on functional out-
come, the level of pain, range of motion of the shoulder
and elbow joint, the rate of secondary interventions and
complications, the time to resumption of work and activ-
ities of daily living, health-related quality of life, costs, and
cost-effectiveness in these patients.
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Study design
The HUMMER trial will follow a multicenter, prospect-
ive observational trial design. Approximately 30 hospi-
tals in The Netherlands will participate.
The decision to provide operative or non-operative
treatment will be left to the discretion of the attending
physician. We chose an observational design because a
randomized controlled trial (RCT) would currently not be
feasible. Many surgeons prefer not to participate in trials
that involve randomization [21] and we know from experi-
ence that patients easily refuse to be randomized between
operative and non-operative treatment. Inclusion prob-
lems were the main reason for failure of a previous RCT
with the same research question as this study [20]. Well-
designed and adequately reported observational studies
are good alternatives to RCTs [22,23]. Preference of obser-
vational studies over RCTs in orthopedic trauma has been
acknowledged [24,25]. They lead to similar outcomes
without the limitations of randomization which may in
practice decrease the validity of the outcomes [26,27].
These designs are increasingly used and accepted in surgi-
cal studies [28]. In order to answer our research question,
we will make adjustments in the statistical analysis by
using the propensity matching score method [29-32].
The trial is registered at the Netherlands Trial Register
(NTR3617).
Recruitment and consent
Eligible persons presenting to the ED with a humeral shaft
fracture will be informed about the trial at the ED. After
an explanation of the study, they will receive information
and a consent form from the attending physician, the clin-
ical investigator, or a research assistant. Patients meeting
all inclusion criteria and none of the exclusion criteria will
be included while they are still at the ED or at the time of
their first outpatient visit.
As with many surgical trials, patients and surgeons can-
not be blinded for treatment. In order to reduce bias, a re-
search physician or research assistant will perform the
follow-up measurements using a standardized protocol.
Radiographs can also not be blinded for treatment; how-
ever, evaluating radiographs in duplicate by two trauma
surgeons independently will improve reliability of fracture
healing assessment. In case of disagreement they will dis-
cuss the results until they reach consensus. Finally, the
analysis will be performed by a statistician without know-
ledge of treatment.
Study population
All persons aged 18 years or older presenting to the ED
with a humeral shaft fracture (AO type 12A or 12B) are
eligible for inclusion [33]. The AO type 12C fractures will
be excluded due to their low occurrence rate. Humeralshaft fractures are defined as fractures located in the area
between the surgical neck and the area immediately above
the supracondylar ridge.
Patients meeting the following inclusion criteria are
eligible for enrolment:
1. Adult men or women aged 18 years or older
(with no upper age limit)
2. A fracture of the humeral shaft, AO class 12A or
12B (confirmed on X-ray)
3. Operation within 14 days after presentation to the
ED (if this is the treatment of choice)
4. Provision of informed consent by patient
If any of the following criteria applies, patients will be
excluded:
1. Patients with concomitant injuries affecting
treatment and rehabilitation of the affected arm
2. Patients with a humeral fracture treated with an
external fixator
3. Patients with a pathological, recurrent or open
humeral shaft fracture
4. Patients with neurovascular injuries requiring
immediate surgery (excl. radial nerve palsy)
5. Additional traumatic injuries of the affected arm
that influence upper extremity function
6. Patients with an impaired upper extremity function
(i.e., stiff or painful arm or neurological disorder of
the upper limb) prior to the injury
7. Retained hardware around the affected humerus
8. Patients with rheumatoid arthritis
9. Bone disorder which may impair bone healing
(excluding osteoporosis)
10.Patients incapable of ensuring follow-up (e.g., no
fixed address or cognitive impairment)
11.Insufficient comprehension of the Dutch language to
understand the rehabilitation program and other
treatment information, as judged by the treating
physician of researcher
Exclusion of a patient because of enrolment in another
ongoing drug or surgical intervention trial will be left to
the discretion of the attending surgeon on a case-by-case
basis.
Intervention
The decision on treatment will be left to the discretion of
the attending surgeon. The choice will be between opera-
tive and non-operative treatment. Also, the rehabilitation
after treatment will not be standardized, but will be pro-
vided as in real life. Although this may create some hetero-
geneity across groups, it will improve the generalizability of
the study results.
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between plate osteosynthesis or intramedullary nailing will
be left to the treating surgeon. No restrictions will be ap-
plied to the approach for reduction and fixation of the
fracture, e.g., open or closed, antegrade or retrograde. The
type and brand of the materials as well as the use of cerc-
lage wires and other elements of the surgery will be left to
the surgeon, local availability and expertise. Critical ele-
ments of the operative treatment will be recorded (e.g.,
type of implant, identification of the radial nerve, surgical
approach, operative delay, duration of surgery) and the ef-
fect on outcome will be assessed.
In order to maximize generalizability, the type of
non-operative treatment will also be left to the attend-
ing surgeon. Usually it consists of a splint, plaster, col-
lar and cuff or hanging cast for 1–2 weeks, followed by
a Sarmiento brace for 4–6 weeks. Critical elements of
this treatment will be recorded and the effect on out-
come will be assessed.
Due to a lack of evidence favoring a particular ap-
proach, the physical therapy and rehabilitation program
will be recorded but not standardized. This will improve
generalization of the study results.
Outcome measures
The Disabilities of the Arm, Shoulder and Hand
(DASH) outcome measure will serve as primary out-
come measure. The DASH is a validated 30-item, self-
report questionnaire designed to help describe the
disability experienced by people with upper-limb disor-
ders and also to monitor changes in symptoms and
function over time [34,35]. It is scored in two compo-
nents: the disability/symptom section (30 items, scored
1–5) and two optional Work and high performance
Sport/Music modules (each 4 items, scored 1–5). The
DASH disability/symptom score is a summation of the
responses to 30 questions on a scale of 1 to 5, with an
overall score ranging from 0 (no disability) to 100 (se-
vere disability). At least 27 of the 30 items must be com-
pleted for a score to be calculated. The DASH optional
modules aim to measure symptoms and function in ath-
letes, performing artists and other workers whose jobs
require a high degree of physical performance. These
optional models are scored separately and each contains
four items, scored 1–5. All items must be completed for
a score to be calculated.
The secondary outcome measures are:
 Constant score
 Pain level at both sides (VAS)
 Range of Motion of the shoulder and elbow joint at
both sides
 Rate of complications
 Rate of secondary interventions Time to resumption of work and other activities of
daily living
 Health-related quality of life: SF-36 and EQ-5D
 Radiographic healing
 Cost of health care use and production loss
 Cost-effectiveness
The Constant score reflects both function and pain [36].
This scoring system consists of four variables that are used
for assessing shoulder function. The right and left shoulder
are assessed separately. The subjective variables are pain
(15 points), activities of daily living (ADL; i.e., sleep, work,
recreation/sport; 10 points), and arm positioning (10
points), which give a total of 35 points. The objective vari-
ables are range of motion (ROM; 40 points) and strength
(25 points), which give a total of 65 points. ROM includes
forward flexion (10 points), lateral elevation (10 points), ex-
ternal rotation related to the head (10 points) and internal
rotation related to the spine column (10 points). ROM will
be measured with a goniometer. Strength of abduction will
be measured using a calibrated spring balance.
Pain level will be determined using a 10-point Visual
Analog Scale (VAS), in which 0 implies no pain and 10
implies the worst possible pain.
The range of motion (ROM) of the shoulder (i.e., ab-
duction and forward flexion) and the elbow joint (i.e.,
flexion and extension) will be measured using a goniom-
eter. Both sides will be assessed separately, and the loss
of ROM will be calculated.
Complications will be recorded from medical charts.
Complications may include: 1) surgical site infection; 2)
wound dehiscence; 3) skin problems (e.g., skin at risk,
skin necrosis); 4) dystrophia; 5) radial nerve palsy; 6)
malunion; 7) implant failure (screw breakout); 8) cuff
pathology; 9) secondary fracture dislocation; or 10) non-
union. Non-union is defined as a failure to heal at
twenty-six weeks post fracture with no progress towards
healing seen on the most recent radiographs [37].
Secondary intervention within one year of initial treat-
ment to promote fracture healing, relieve pain, treat infec-
tion, or improve function will be recorded from medical
charts. Interventions will be categorized as: 1) osteosynth-
esis with or without bone grafting; 2) implant exchange
with or without bone grafting; 3) implant removal; 4) inci-
sion and drainage for superficial surgical site infection; or
5) incision and drainage for deep surgical site infection.
The indication and admission duration for all intervention
will also be recorded.
Presence of radiographic healing will be determined
using X-rays. Fracture consolidation is defined when one
of the three criteria listed is present; 1) bridging of frac-
ture by callus/bone trabeculae or osseous bone; 2) oblit-
eration of fracture line/cortical continuity; or 3) bridging
of fracture at three out of four cortices.
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ing will be recorded using a custom-made questionnaire.
The Short-Form 36 (SF-36) is a validated multi-purpose,
health survey with 36 questions, representing eight health
domains that are combined into a physical and a mental
component scale [38]. The Physical Component Summary
(PCS) combines the health domains physical functioning
(PF; 10 items), role limitations due to physical health (RP;
4 items), bodily pain (BP; 2 items), and general health per-
ceptions (GH; 5 items). The Mental Component Summary
(MCS) combines the health domains vitality, energy, or fa-
tigue (VT; 4 items), social functioning (SF; 2 items), role
limitations due to emotional problems (RE; 3 items), and
general mental health (MH; 5 items). Scores ranging from
0 to 100 points are derived for each domain, with lower
scores indicating poorer function. These scores will be
converted to a norm-based score and compared with the
norms for the general population of the United States
(1998), in which each scale was scored to have the same
average (50 points) and the same standard deviation (10
points).
The EuroQol-5D is a validated questionnaire for meas-
uring health-related quality of life [39,40]. Its use is recom-
mended for assessing quality of life in trauma patients,
especially for economic assessments [41,42]. The EQ-5D
descriptive system consists of five dimensions of health
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression). Scores are converted to a utility score
ranging from zero to one, with lower scores indicating
poorer quality of life. The EQ VAS records the respon-
dents self-rated health status on a vertical (0–100) visual
analog scale.
The cost-effectiveness analysis will be performed from a
societal perspective and will include costs for health care
and production losses. Patients will be asked to complete
a custom-made questionnaire that contains detailed infor-
mation on both items. Health care costs will include gen-
eral practice care, medical specialist care, nursing care,
physical therapy, hospitalization, medication, home care,
and other costs directly associated with diagnosis, treat-
ment, and rehabilitation.
In addition to the outcome variables mentioned above,
the following data will be collected:
a) Intrinsic variables (baseline data): age, gender,
American Society of Anesthesiologists’ASA classification, to-
bacco consumption, alcohol consumption, comorbidities (in-
cluding osteoporosis), dominant side, and medication use.
b) Injury related variables: affected side, mechanism of
injury, fracture classification according to the AO classifi-
cation system, additional injuries, and admission duration.
c) Intervention-related variables: time between injury
and start of treatment, days of collar and cuff, sling or
plaster, time between injury and start of physical ther-
apy, and number of physical therapy sessions.Study procedures
Clinical evaluation will occur at two weeks (7–21 days
window), six weeks (4–8 weeks window), three months
(11–15 weeks window), six months (6–7 months win-
dow), and 12 months (12–14 months window) after start
of treatment [Table 1]. These visits are standard of care
for the targeted patient group. At each follow-up visit,
the research coordinator or research assistant will ascer-
tain patient status (i.e., adverse events/complications,
secondary interventions, etcetera, and will verify infor-
mation within medical records).
At each follow-up visit, the range of motion of the
shoulder and elbow will be measured using a goniometer
by a physician or research assistant. In addition, patients
will be asked to complete the questionnaires relating to
disability (DASH score including optional modules), pain
(VAS), health-related quality of life (SF-36, EQ-5D), health
care consumption and production loss. From six weeks
onwards, the research coordinator or research assistant
will determine the Constant score.
At each clinical follow-up visit, anterior-posterior and
lateral radiographs are generally routinely obtained. All
images available from three months onwards will be ana-
lyzed. Apart for the 6-month follow-up, during which X-
rays are needed for assessing signs of nonunion, local
radiographical protocols will apply. For this reason, the
follow-up at six month should not be done earlier. In
case no radiographic healing is seen at six months, an
X-ray at 12 months is also required. At the last visit, the
surgeon or researcher will also document any secondary
intervention that is planned for the patient.Sample size calculation
Calculation of the required sample size for the primary
analysis is based on the assumption that the mean
DASH in the non-operative group will be 16, with a
Standard Deviation (SD) of 16 [8]. We expect less dis-
ability (i.e., lower DASH score) at three months in the
operative group; the expected DASH score in the opera-
tive group will be 10 (SD 10) [8]. A two-sided test with
an α level of 0.05 and a β level of 0.2 requires 78 patients
in every group. In order to account for loss of patients
due to mortality (10%) and loss-to-FU (10% anticipated
based upon previous studies by the research team), a
sample size of 95 patients per group is needed.
Results of a retrospective study assessing clinical out-
come of humeral shaft fractures, showed that 45-55% of
all AO-subclasses were treated operatively [18]. In order
to assess whether functional outcome scores differ be-
tween the fracture subtypes, a minimum of 2x20 patients
per fracture subtype is sufficient. In order to achieve
that, we need to include until at least 200 patients in
both the operative groups and the non-operative group.
Table 1 Schedule of events
Radiographs & events Screening Enrolment Baseline Post 2 weeks 6 weeks 3 months 6 months 12 months
surgery (7–21 d) (4–8 we) (11–15 we) (6–7 mo) 12-14 mo)




Surgical report form X
DASH X X X X X
Pain (VAS) X X X X X
SF-36 X X X X X
EQ-5D X X X X X
Clinic FU X X X X X
Range of motion X X X X X
Secondary interventions X X X X X
Complications X X X X X
Health care consumption X X X X X
ADL/work resumption X X X X X
Physical therapy X X X X X
Constant score X X X X
Early withdrawal * * * * *
1X-rays will be taken according to local protocol; all X-rays after three months will be analyzed. The six-month X-ray is needed for assessing fracture healing.
If no signs of healing are seen at six months, the 12-month X-ray is also required.
*Only at time of withdrawal.
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during the propensity score matching. Although we do
not have a-priori data to determine how many patients
will be lost, the 400 targeted patients will be more than
sufficient.
Statistical analysis
Data will be analyzed using the Statistical Package for
the Social Sciences (SPSS) version 21 or higher (SPSS,
Chicago, Ill., USA) and will be reported following the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) guidelines. Normality of con-
tinuous data will be assessed by inspecting the frequency
distributions (histograms), and homogeneity of variances
will be tested using the Levene’s test.
Descriptive analysis will be performed to report baseline
characteristics (intrinsic variables and injury-related vari-
ables) and outcome measures for both treatment groups.
For continuous data mean and SD (parametric data)
or medians and percentiles (non-parametric data) will be
calculated and reported. For categorical data, numbers
and frequencies will be calculated and reported for both
treatment groups.
Univariate analysis will be performed in order to test
the difference in the primary and secondary outcome
measures between the operative and the non-operativegroup. Continuous data such as the DASH score at the
different time points (primary outcome) will be tested
using a Student’s T-test (parametric data) or a Mann
Whitney U-test (non-parametric data). Chi-square ana-
lysis will be used for statistical testing of categorical data
such as the nonunion rate. A p-value <0.05 will be taken
as threshold of statistical significance.
For the primary analysis, a mixed linear regression
model will be developed in order to model the relation
between different covariates and the DASH score over
time. Intrinsic and fracture-related variables that display
a p-value <0.5 in univariate analyses will be added as co-
variate. Similar models will be developed for the Con-
stant, SF-36, and EQ-5D score. Subgroup analysis (e.g.,
elderly versus <65 years) will be performed.
For the secondary analysis we will develop a propensity
score model as published before [43,44]. Characteristics
including fracture type, age, gender, mechanism of injury,
dominance, and activity levels will be included in this
model; the resulting propensity score represents the
chance of being operated. Next, the logit of the propensity
score will be used in order to match each patient receiving
operative treatment with one or more patients receiving
non-operative treatment. The effect of operative treatment
will be analyzed with linear or ordinal logistic mixed ef-
fects regression analysis taking the matched-pairs design
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performed using a McNemar test (for categorical data),
and a paired sample t test (parametric, continuous data)
or a Wilcoxon signed rank test.
The economic evaluation will be performed from a so-
cietal perspective. Costs will be measured in accordance
with Dutch guidelines for economic evaluations, using
standard cost prices as published by Hakkaart-Van Rooijen
et al. where possible [45]; effects will be discounted at a
rate of 1.5% and costs at 4% per year [45]. The incremental
cost-effectiveness ratio (ICER) of operative versus non-
operative treatment will be expressed in a cost-utility ratio
(i.e., cost per QALY) using the EQ-5D utility score as ef-
fect measure. Uncertainty around this ratio will be pre-
sented using confidence ellipses on the cost-effectiveness
plane and acceptability curves.
Ethical considerations
The study will be conducted according to the principles of
the Declaration of Helsinki (59th World Medical Associ-
ation General Assembly, Seoul, October 2008). This study
has been given a waiver of consent by the medical research
ethics committee (MREC); in Dutch: Medisch Ethische
Toetsings Commissie (METC). Following review of the
protocol, the MREC concluded that this study is not sub-
ject to the Medical Research Involving Human Subjects
Act (WMO). They concluded that the study is a medical/
scientific research, but no patients are subjected to proce-
dures or are required to follow rules of behavior. Conse-
quently, the statutory obligation to provide insurance for
subjects participating in medical research (article 7, Sub-
section 6 of the WMO and Medical Research (Human
Subjects) Compulsory Insurance Decree of 23 June 2003)
was also waived.
The MREC Erasmus MC (Rotterdam, The Netherlands)
acts as central ethics committee for this trial (reference
number MEC-2012-296). Approval has been obtained
from the local hospital boards in all participating centers.
Discussion
The HUMMER trial will study outcome after operative
versus non-operative treatment of humeral shaft fractures.
Operative treatment is expected to result in earlier recov-
ery than non-operative treatment. Earlier functional recov-
ery will result in a better quality of life of patients, earlier
work and ADL resumption, a higher level of indepen-
dency, and less health care needs. Although costs for ini-
tial treatment will be higher in the operative group (due to
surgery), we hypothesize that costs will be saved by less
health care needs during the recovery process and less
productivity loss. Despite higher initial costs, we expect
that primary surgery will be more cost-effective. To the
best of our knowledge, this is the first high-quality multi-
center prospective observational study that will look atpatient, medical and societal perspective in patients with a
humeral shaft fracture.
Thirty hospitals in the Netherlands will participate. In-
clusion of patients has started October 01, 2012 and the
expectation is to include 10 patients per month. With a
follow-up of one year the presentation of data will be ex-
pected in the beginning of 2016.
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